Patients in that study showed evidence of a halt in disease progression lasting six to twelve months after a single intravitreous injection of AdPEDF.
and
New therapies to treat AMD have demonstrated benefit but these therapies must be injected every four to six weeks. GenVec believes its gene transfer approach may provide an effective and more convenient treatment for AMD.
I am not much in favor of adenoviral approach, but it's a way to solve frequent injection problem, just as Oxigene is trying to do.
Market Data 
Markets 
AI
